• Home
  • About
    • Our Constitution
    • Chairman’s words
    • Chairman and Board Members
  • Members
    • Become a Member
  • Annual Meetings
    • 1st Annual Meeting – 2010
    • 2nd Annual Meeting – 2011
    • 3rd Annual Meeting – 2012
    • 4th Annual Meeting -2013
    • 5th Annual Meeting- 2014
    • 7th Annual Meeting -2016
    • 8th Annual Meeting -2017
    • 9th Annual Meeting -2018
    • 10th Annual Meeting
    • 11th Annual Meeting
    • 13th Annual Meeting
  • Abstracts
    • Abstracts 2010
    • Abstracts 2011
    • Abstracts 2012
    • Abstracts 2014
    • Abstracts 2015
    • Abstracts 2016
    • Abstracts 2017
    • Abstracts 2018
    • Full Abstract List
  • Organizations
    • ISMFM
    • Israel Medical Association
    • Placenta – The Official Jourmal of IFPA
    • The Israel Fertility Association
    • SMFM
    • International Federation of Placenta Associations
    • The Endocrine Society of Australia
    • Nano Science
    • The Society for Reproductive Biology
    • Australasian Diabetes in Pregnancy Society
    • Society of Theriogenology
    • American College of Theriogenologists
    • The Fetal Medicine Foundation
  • Contact
Menu
  • Home
  • About
    • Our Constitution
    • Chairman’s words
    • Chairman and Board Members
  • Members
    • Become a Member
  • Annual Meetings
    • 1st Annual Meeting – 2010
    • 2nd Annual Meeting – 2011
    • 3rd Annual Meeting – 2012
    • 4th Annual Meeting -2013
    • 5th Annual Meeting- 2014
    • 7th Annual Meeting -2016
    • 8th Annual Meeting -2017
    • 9th Annual Meeting -2018
    • 10th Annual Meeting
    • 11th Annual Meeting
    • 13th Annual Meeting
  • Abstracts
    • Abstracts 2010
    • Abstracts 2011
    • Abstracts 2012
    • Abstracts 2014
    • Abstracts 2015
    • Abstracts 2016
    • Abstracts 2017
    • Abstracts 2018
    • Full Abstract List
  • Organizations
    • ISMFM
    • Israel Medical Association
    • Placenta – The Official Jourmal of IFPA
    • The Israel Fertility Association
    • SMFM
    • International Federation of Placenta Associations
    • The Endocrine Society of Australia
    • Nano Science
    • The Society for Reproductive Biology
    • Australasian Diabetes in Pregnancy Society
    • Society of Theriogenology
    • American College of Theriogenologists
    • The Fetal Medicine Foundation
  • Contact
Facebook
Third Stage Retained Placental Fragments: Risks Associated With An Unsolved Conundrum
Home ‹ 2015 Abstracts ‹ Third Stage Retained Placental Fragments: Risks Associated With An Unsolved Conundrum

Maayan Bas-Lando, Lior Drukker, Rivka Farkash, Arnon Samueloff, Sorina Grisaru Granovsky

Shaare Zedek Medical Center, Hebrew University Medical School, Jerusalem

Introduction: The third stage of labor is a major source to maternal morbidity and mortality. We aimed to determine the maternal risks associated with a third stage uterine revision procedure due to retained placental fragments (3rd SRPF).

Materials & Methods: Cohort of women, 2005 -2014, based on a validated computerized database at a single center. Women with vaginal delivery (VD) and 3rd SRPF were compared to women with spontaneous VD and normal third stage, controls. Main outcome: puerperal febrile morbidity and maternal blood transfusion. Department protocol for the procedure: sterile procedure field preparation, prophylactic antibiotics (1 gr Cefazoline IV), appropriate anesthesia/ analgesia, VD to procedure interval 0-40 minutes.  Comparisons as appropriated and adjusted multivariate model produced OR (95%CI), p <0.05

Results: During the study 101,185 women had a VD; 3297 (3.3%) had revision of the uterine cavity due to 3rd SRPF. All women had the management protocol implemented as registered in the real time database. Groups characteristics in Table. Women with 3rd SRPF as compared to controls had a significantly increased rate of postpartum febrile morbidity 15(0.5%) vs 111 (0.1%) p<0.0001, hemorrhage control interventions [Bakry 4(0.0012%), hysterectomy 11 (0.334%)] p<0.00001, blood products transfusion 298 (9%) vs 507 (0.5%), p<0.0001. Furthermore, a multivariate analysis adjusted for potential confounders: maternal age>35years, epidural, past CS, ART, preterm<37weeks, primiparity, SGA, preeclampsia, induction of labor, instrumental delivery, newborn gender: 3rd SRPF emerged as a significant risk for febrile morbidity OR 3.4(2.41-4.90) p<0.0001, hemoglobin drop [>3 g%] OR 8.18 (7.45-8.98), p<0.0001 and blood products transfusion OR 17.66 (15.13-20.61) p<0.0001.

Conclusions: Strict implementation of a 3rd SRPF uterine revision management protocol is nonetheless associated with severe maternal morbidity. The prospective evaluation of an improved approach to 3rd SRPF is crucial for maternal health.

Demographic and labor group characteristics

3rd SRPF Control P value
Age (years) (mean, SD) 28.3±5.6 29.0±5.7 P<0.0001
Age> 35 years (N, %) 514 (15.6%) 12,280 (12.5%) P<0.0001
Past CS (N, %) 335 (10.2%) 7,114 (7.3%) P<0.0001
Preeclampsia

(N, %)

57 (1.7%) 784 (0.8%) P<0.0001
ART (N, %) 208 (6.3%) 2,668 (2.7%) P<0.0001
Induction of labor (N, %) 402 (12.2%) 7,950 (8.1%) P<0.0001
Instrumental delivery (N, %) 313 (9.5%) 5,400 (5.5%) P<0.0001
Epidural analgesia (N, %) 2,129 (64.6%) 51,168 (52.3%) <0.0001
Primiparity (N, %) 792 (24%) 23,594 (24.1%) P=0.915
Preterm delivery <37weeks (N, %) 276 (8.4%) 3,348 (3.4%) P<0.0001
SGA (N, %) 272 (8.2%) 6,580 (6.7%) P<0.0001
Prior >3 miscarriages 173 (5.2%) 3,364 (3.4%) P<0.0001
Newborn gender, female (N, %) 1,789 (54.3%) 47,583 (48.6%) P<0.0001
Fever (N, %) 15 (0.5%) 111 (0.1%) P<0.0001
Hysterectomy

(N, %)

11 (0.334%) 0 (0%) P<0.00001
Transfusion of blood products

(N, %)

298 (9%) 507 (0.5%) P<0.0001
Prolonged hospitalization (>3days) 690 (21%) 11,102 (11.4%) P<0.0001
« Previous
Next »
Powered by Netmii and Art + Web
All rights reserved to ISPR -Israel Society for Placental Research
Scroll to top